Despite concerns regarding hypoglycemia, the longer-acting nature of efsitora presents promising options for improved glucose control in type 2 diabetes.

Experts have raised concerns about the increased risk of mild hypoglycemia associated with efsitora, particularly during the first 12 weeks of treatment, suggesting that continuous glucose monitoring may be beneficial.

Overall, efsitora's promising results and innovative approach could represent a significant advancement in diabetes management.

Eli Lilly and Co. recently announced results from three Phase 3 clinical trials—QWINT-1, QWINT-3, and QWINT-4—focused on the once-weekly insulin efsitora alfa for adults with type 2 diabetes.

In the QWINT-1 trial, efsitora demonstrated a reduction in A1C levels by 1.31%, slightly outperforming insulin glargine, which showed a reduction of 1.27% after 52 weeks.

Efsitora also exhibited a safety profile comparable to daily basal insulin therapies, with some trials indicating significantly fewer hypoglycemic events.

The innovative fixed-dose regimen of efsitora in QWINT-1, which includes only four titration levels, is designed to simplify the initiation of insulin therapy for patients.

The QWINT clinical trial program, which began in 2022, enrolled over 3,000 participants across multiple countries, highlighting the global interest in this treatment innovation.

Results from the trials were presented at the American Diabetes Association's 85th Scientific Sessions on June 22, 2025, and subsequently published in the New England Journal of Medicine and The Lancet.

Lilly plans to submit efsitora for regulatory approval for the treatment of type 2 diabetes by the end of 2025, potentially reducing the burden of insulin therapy with fewer injections.

The potential approval and market availability of efsitora will depend on factors such as cost, convenience, and competition from newer noninsulin medications like GLP-1 receptor agonists.